HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies.

Abstract
COL-3 is an oral, lipophilic, tetracycline analog that has been administered to patients with metastatic cancer. Preliminary assessment of COL-3 in 35 patients with refractory metastatic carcinoma demonstrated apparent nonlinear pharmacokinetics with highly variable oral clearance (63.9% coefficient of variance [CV]). To elucidate possible sources of variability of COL-3 pharmacokinetics in vivo, in vitro plasma protein binding and in vitro metabolism were explored along with in vivo pharmacokinetics using compartmental modeling. The variability in the overall clearance and urinary excretion of COL-3 was also assessed. COL-3 had a long terminal half-life (median = 59.8 h), large apparent volume of distribution (median = 50.2 L), and low apparent clearance (median = 9.93 mL/min). Only adjusted ideal body weight decreased the variability in total apparent clearance. There was nonsaturable plasma protein binding of COL-3 (fu = 5.5%), with the majority of binding to albumin. The renal route of elimination is negligible, with 0.06% of unchanged COL-3 and 3.31% COL-3 glucuronide excreted in the first 6 days. COL-3 is not metabolized by phase I metabolism but does undergo glucuronidation in vitro by UGT1A1, UGT1A3, UGT1A9, and UGT2B7 and in vivo, as evidenced by COL-3 glucuronides in the urine (median = 13.6% of the total dose). COL-3 exhibits nonlinear pharmacokinetics, possibly due to dissolution rate-limited absorption.
AuthorsMichelle A Rudek, Jürgen Venitz, Yuichi Ando, Eddie Reed, James M Pluda, William D Figg
JournalJournal of clinical pharmacology (J Clin Pharmacol) Vol. 43 Issue 10 Pg. 1124-35 (Oct 2003) ISSN: 0091-2700 [Print] England
PMID14517195 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Glucuronides
  • Matrix Metalloproteinase Inhibitors
  • Orosomucoid
  • Serum Albumin
  • Tetracyclines
  • tetracycline CMT-3
  • Cytochrome P-450 Enzyme System
  • Matrix Metalloproteinases
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Cytochrome P-450 Enzyme System (metabolism, physiology)
  • Dose-Response Relationship, Drug
  • Female
  • Glucuronides (blood, urine)
  • Humans
  • Male
  • Matrix Metalloproteinase Inhibitors
  • Matrix Metalloproteinases (metabolism, pharmacokinetics)
  • Middle Aged
  • Neoplasm Metastasis (therapy)
  • Orosomucoid (chemistry)
  • Pharmacokinetics
  • Protein Binding (drug effects, physiology)
  • Serum Albumin (chemistry)
  • Tetracyclines (metabolism, pharmacokinetics)
  • Time Factors
  • Treatment Failure

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: